MAPT and Parkinson disease: Beyond Alzheimer's disease, the modular sensor architecture can be adapted for other neurodegenerative diseases—including Parkinson's and frontotemporal dementia—by targeting biomarkers such as α‐synuclein and p‐tau 217.